IAN Block Techniques and Articaine’s Role in Local Anesthesia

The inferior alveolar nerve block, commonly called the IAN block, is the most widely used injection technique for numbing the lower jaw during dental procedures, yet it fails more often than most patients realize. Even experienced clinicians encounter cases where the standard injection simply does not produce adequate numbness, and that reality has driven decades of research into alternative techniques and better anesthetic drugs. Articaine, an amide local anesthetic with unusual chemical properties, has become central to that effort because of its ability to penetrate bone and soft tissue more effectively than the longtime default, lidocaine.

Why the Standard IAN Block Fails

The conventional IAN block targets the inferior alveolar nerve just before it enters a bony canal in the lower jaw. When it works, it numbs the teeth, lower lip, and chin on that side. When it does not, the culprit is usually anatomical variation. The nerve does not always sit where textbooks say it should, and the bony landmarks clinicians use to guide needle placement vary from person to person. The nerve may branch earlier than expected, or accessory nerves may supply some teeth independently of the main trunk. Even in the hands of an expert, the block can miss its target.¹

Inflammation complicates things further. When a tooth is acutely infected or inflamed, the surrounding tissue becomes acidic. Local anesthetics are weak bases that need to cross cell membranes in their uncharged form to work. An acidic environment keeps more of the anesthetic in its charged, water-soluble form, which cannot easily enter nerve cells. This is why the teeth that need the most work, like those with irreversible pulpitis (a severely inflamed pulp), are often the hardest to numb.

Alternative Techniques for the Lower Jaw

When the standard approach does not work, clinicians have several other injection techniques to draw on. The two best-studied alternatives are the Vazirani-Akinosi (closed-mouth) technique and the Gow-Gates technique. Each targets the nerve at a different anatomical point and uses different landmarks.

The Vazirani-Akinosi technique is performed with the mouth closed, which makes it especially useful for patients who have difficulty opening wide, including those with trismus (jaw stiffness from infection or inflammation). In one comparative trial, the Vazirani-Akinosi technique achieved the highest anesthetic success rate at about 96%, significantly outperforming the Gow-Gates approach.² It also tends to produce less injection pain and a very low incidence of trismus afterward. Another study found that beginners had fewer failed blocks with the Vazirani-Akinosi technique than with the conventional IAN block, suggesting it may be more forgiving of imperfect needle placement.³

The Gow-Gates technique aims higher on the nerve trunk, closer to the base of the skull, and theoretically anesthetizes a broader area. However, it comes with trade-offs. One prospective comparison found that onset of numbness was slower with Gow-Gates (about five minutes versus roughly three to three and a half for the conventional and Vazirani-Akinosi methods), and patients reported more pain during the injection itself. The incidence of trismus after the procedure was also higher at around 20%, compared to 5% with the conventional block.⁴ So while Gow-Gates can rescue a failed conventional block by targeting a different spot, it is not a painless upgrade.

What Makes Articaine Different

Most dental local anesthetics belong to the amide family and share a similar basic structure. Articaine is an amide too, but with two features that set it apart: a thiophene ring in place of the benzene ring found in drugs like lidocaine, and an ester linkage built into its molecular chain.⁵ The thiophene ring increases the molecule’s fat-solubility, which matters because it has to cross fatty cell membranes to reach the sodium channels inside nerve cells. The ester group gives the body a fast way to break articaine down. Enzymes in the blood can cleave that ester bond quickly, so the drug’s half-life in the bloodstream is short, roughly 20 minutes, compared to about 90 minutes for lidocaine. Faster clearance lowers the risk of systemic toxicity when the drug enters the general circulation.

That combination of features, high fat-solubility for getting in and rapid metabolism for getting out, allows articaine to be used at a higher clinical concentration (4%) than lidocaine (2%) without proportionally increasing the risk of overdose.⁶ Molecular dynamics research has also proposed an additional mechanism: articaine can form intramolecular hydrogen bonds that shift its lipophilicity depending on the surrounding environment, potentially enhancing its ability to diffuse through connective tissue and bone.⁷ This superior tissue diffusion is one reason articaine performs well as a buccal infiltration injection in the lower jaw, a location where lidocaine infiltrations historically struggle because of the thick cortical bone of the adult mandible.

Articaine Versus Lidocaine for IAN Blocks

Head-to-head comparisons between articaine and lidocaine for standard IAN blocks tell a nuanced story. In routine procedures, the two drugs often perform similarly. A meta-analysis of randomized trials found that for nerve block anesthesia, articaine had a slightly shorter onset (about a quarter of a minute faster) and a substantially longer duration (roughly 54 minutes longer), but the success rates for achieving adequate numbness were not significantly different between the two.⁸

The picture shifts when the patient has an acutely inflamed tooth. A network meta-analysis looking specifically at patients with irreversible pulpitis ranked articaine’s probability of success at about 73%, compared to roughly 12% for lidocaine for the IAN block in that population.⁹ That is a stark gap. A randomized trial in the same patient population found less dramatic but consistent results: articaine achieved a 97% success rate during access cavity preparation, versus 93% for lidocaine, though the difference was not statistically significant. During deeper instrumentation of the root canals, the two drugs performed almost identically, at about 71–72%.¹⁰ The takeaway is that articaine’s advantage over lidocaine is most apparent in the hardest-to-numb situations, and even then, deep pulpal work can challenge any anesthetic.

Onset and Duration in Practice

Speed matters in a dental office. Both the patient and the clinician benefit when numbness arrives quickly and lasts long enough to complete the procedure without reinjection. In maxillary infiltration, one study measured a pulpal onset of about 1.4 minutes for 4% articaine with 1:100,000 epinephrine, compared to 2.8 minutes for 2% lidocaine with the same concentration of epinephrine. The duration difference was even more pronounced: about 66 minutes for articaine versus 39 minutes for lidocaine.¹¹

For IAN blocks during surgical procedures like third molar removal, a comparative trial found articaine’s onset at about 57 seconds versus 88 seconds for lidocaine, and its duration at roughly 231 minutes versus 175 minutes.¹² That extra hour of numbness is clinically meaningful for longer procedures but can be a nuisance for the patient afterward during simple fillings, when lingering numbness just means accidentally biting a numb lip over lunch.

Buccal Infiltration as an Alternative to the Nerve Block

One of articaine’s most practical advantages is that it can sometimes replace the IAN block entirely. Because it diffuses through bone more readily than lidocaine, a simple injection into the gum tissue on the cheek side of a lower tooth (a buccal infiltration) can deliver enough anesthetic through the jawbone to numb the tooth’s nerve. This approach avoids the deeper, more uncomfortable nerve block injection altogether.

In children needing extraction of primary lower molars, a randomized trial found that a buccal infiltration with 4% articaine produced equivalent pain control to a conventional IAN block with 2% lidocaine, with no significant difference in pain behavior scores. The authors concluded that clinicians could avoid the IAN block in pediatric patients for this type of procedure.¹³

In adults, the evidence supports articaine buccal infiltration as a supplement more than a standalone replacement for the IAN block in posterior teeth. A study of patients who received a lidocaine IAN block found that adding a supplementary articaine buccal infiltration significantly boosted success rates across first molars, premolars, and lateral incisors. For first molars, success jumped from 20 of 40 volunteers to 33 of 40 with the added infiltration.¹⁴ For anterior teeth and premolars with intact pulps, a standalone articaine infiltration often works well. For molars, especially inflamed ones, the combination of an IAN block plus articaine infiltration is the more reliable strategy.

Epinephrine Concentration and Cardiovascular Effects

Articaine is commercially available in two formulations that differ in their epinephrine (adrenaline) concentration: 1:100,000 and 1:200,000. Epinephrine constricts blood vessels at the injection site, slowing the rate at which the anesthetic is carried away into the bloodstream. This extends the duration of numbness and reduces the peak blood concentration of the drug. In dentistry, the relevant question is whether the higher epinephrine concentration actually produces meaningfully better anesthesia or just more cardiovascular stimulation.

Two controlled clinical trials found that the 1:200,000 formulation provided pulpal anesthesia comparable to the 1:100,000 version in both mandibular and maxillary applications. Onset times and durations were similar.¹⁵ The difference showed up on the cardiovascular side: the 1:100,000 formulation produced significantly greater elevations in heart rate and systolic blood pressure at the ten-minute mark.¹⁶ A more recent randomized study confirmed this pattern, finding that the 1:100,000 concentration produced a greater and more sustained heart rate elevation compared to 1:200,000 during IAN blocks.¹⁷

For healthy patients, neither formulation poses serious cardiovascular risk. But for patients with uncontrolled hypertension, certain heart conditions, or those taking medications that interact with epinephrine, the 1:200,000 formulation offers a meaningful safety margin without sacrificing anesthetic effectiveness.

Articaine in Children

The use of articaine in pediatric dentistry has been debated, partly because of older regulatory caution about its use in very young children and partly because of concerns about lip or cheek biting during the prolonged numbness that follows. The evidence, however, has been reassuring. A meta-analysis comparing adverse effects of articaine and lidocaine in pediatric patients found no significant difference in the probability of adverse reactions between the two drugs. There was no significant difference in postoperative pain, soft tissue injury, or swelling either.¹⁸

Even in children under four years old, where data is thinnest and caution has historically been greatest, an observational study of supraperiosteal (above-the-bone) articaine injections found no adverse events directly linked to the drug.¹⁹ A broader review of the literature noted that articaine has been documented as safe in children of all ages, with retrospective data going back to 1989 showing no adverse reactions in over 200 pediatric cases.²⁰ The main practical concern remains soft tissue injury from biting: children who are numb for a long time after a procedure may chew on their lip or tongue without realizing it. Clinicians often address this by using the lower epinephrine concentration or by choosing infiltration over a nerve block to limit both the area and duration of numbness.

Paresthesia and Safety Concerns

One persistent concern about articaine is whether it carries a higher risk of paresthesia, a lingering numbness or tingling that persists long after the anesthetic should have worn off. Reports from the early 2000s suggested that articaine (and prilocaine) were disproportionately associated with paresthesia following IAN blocks. The question is whether this reflects genuine neurotoxicity from the higher concentration (4% versus 2% for lidocaine) or simply reflects the fact that articaine became enormously popular in many markets, so more cases were reported purely because more injections were given.

The neurotoxicity question remains unresolved. Laboratory research has shown that Schwann cells (the cells that insulate nerve fibers) exposed to articaine display different patterns of damage compared to those exposed to lidocaine, suggesting the two drugs affect nerve tissue through distinct pathways.⁶ Whether this translates to a clinically meaningful difference in paresthesia risk for patients is still debated. Paresthesia following dental nerve blocks is rare regardless of the anesthetic used, with reported incidence rates well below 1%. Most cases resolve on their own within weeks to months. Persistent paresthesia lasting more than six months is exceptionally uncommon. For patients, the practical message is that the risk exists with any local anesthetic delivered near a nerve trunk, and the choice between articaine and lidocaine is unlikely to be the deciding factor in whether paresthesia occurs.

Rescue Strategies When Nothing Seems to Work

Even with the best technique and the best drug, some patients remain partially numb or not numb at all. This is most common during emergency treatment of teeth with severe pulpitis. When a standard IAN block fails, clinicians have a menu of escalating options.

The first step is often a supplementary buccal infiltration with articaine, as described earlier. If that is not sufficient, intraosseous injection is a reliable next move. This involves placing a small hole through the cortical bone near the tooth and injecting anesthetic solution directly into the cancellous (spongy) bone. A study of patients whose IAN blocks had failed found that adding an intraosseous injection raised the success rate from 42% to 90% for first molars. Every patient who received the combination achieved at least some anesthesia, whereas about a third of patients with the IAN block alone never reached adequate numbness.²¹ The onset of anesthesia was essentially immediate. A study using a specialized intraosseous delivery system (X-tip) in patients with irreversible pulpitis who had failed IAN blocks reported a 93% success rate.²²

Other rescue options include intrapulpal injection (depositing anesthetic directly into the exposed pulp chamber under pressure, which is effective but can be briefly painful), intraligamentary injection (into the periodontal ligament space around the tooth), and switching to an alternative block technique like the Vazirani-Akinosi or Gow-Gates. Experienced clinicians typically work through these options in a logical sequence rather than simply reinjecting the same failed block, which rarely works a second time for the same anatomical or inflammatory reasons that caused the initial failure.

Genetic Factors That Affect Numbness

A small number of patients seem consistently harder to numb, and genetics may play a role. Inherited channelopathies, conditions caused by genetic variations in the voltage-gated sodium channels that local anesthetics target, can alter how nerve cells respond to the drug. When regional anesthesia fails repeatedly without an obvious anatomical or inflammatory explanation, these genetic variations are worth considering.²³

The most widely discussed genetic association involves red hair. The melanocortin-1 receptor gene (MC1R), which produces the red-hair phenotype, has been linked to altered pain sensitivity and possibly altered anesthetic requirements. Popular belief holds that redheaded patients are harder to numb. The laboratory and survey data supporting this idea are mixed. A controlled study specifically measuring the anesthetic efficacy of IAN blocks in red-haired versus non-red-haired women found no significant differences in anesthetic success for any of the teeth tested.²⁴ So while the biological plausibility exists, the clinical evidence that redheaded patients routinely need more anesthetic during dental procedures is thin. The more relevant clinical takeaway is that when a patient reports a history of being hard to numb, the clinician should take that seriously and plan accordingly, regardless of hair color.

Cost and Practical Trade-Offs

Articaine costs more per cartridge than lidocaine in most markets. A systematic review that combined clinical efficacy data with market pricing found that lidocaine with epinephrine was the most cost-effective option for IAN blocks in lower molars with irreversible pulpitis, while bupivacaine was the least cost-effective despite its long duration. Articaine’s higher cost, despite its diffusion advantages, limits its routine use as a first-line agent in some practice settings.²⁵

In practice, many dental offices stock both drugs and use them strategically. Lidocaine remains the workhorse for routine procedures where its lower cost and familiar safety profile make it the default. Articaine gets reserved for situations where its strengths matter most: supplementary buccal infiltrations, cases where the IAN block has failed or is expected to be difficult, procedures on inflamed teeth, and cases requiring faster onset or longer duration. Pediatric offices may prefer articaine infiltrations specifically to avoid nerve blocks in young children. The decision is rarely about one drug being “better” across the board; the two anesthetics occupy complementary niches in the same clinical toolkit.